Insmed reported $757.49M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
DBV Technologies USD 160.4M 47.5M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 757.49M 52.64M Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026